Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: a single center experience

Orally administered targeted therapies, including ibrutinib, are increasing used to treat non-Hodgkin lymphoma, however, little is known about the clinical impact of suboptimal dosing. Data on reasons and timeframes for ibrutinib discontinuation, dose reductions and treatment interruptions were collected on 170 non-Hodgkin lymphoma and chronic lymphocytic leukemia patients treated with ibrutinib at a single institution. Discontinuation of ibrutinib therapy was associated with poor outcome as previously reported. We also show that discontinuation of therapy for reasons other than progression and reduction of ibrutinib dose were associated with poor outcome. Patients also demonstrated poor progression-free and overall survival related to suboptimal dose adherence of ibrutinib which was predominantly due to early dose reduction rather than temporary dose holds. These data support recommendations for full dose at treatment initiation and allowing for short duration dose holds as needed.

Source: Clinical Lymphoma, Myeloma and Leukemia - October 12, 2018 Category: Hematology Authors: AnnaLynn M. Williams, Andrea Baran, Carla Casulo, Patrick Reagan, Jonathan W. Friedberg, Margaret Helber, Jeremiah Moore, Elizabeth Baloga, Clive S. Zent, Paul M. Barr Source Type: research